For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online April 30 in the Annals of Internal Medicine.
Semaglutide alleviates metabolic-linked liver disease in people with HIV retrieved 30 April 2024 from https://medicalxpress.com/news/2024-04-semaglutide-alleviates-metabolic-linked-liver.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Endoscopic sleeve gastroplasty is cost saving versus semaglutide, finds studyFor individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published online April 12 in JAMA Network Open.
Read more »
Unveiling the key role of RNA modification in HIV-1 survival and replicationA chemical modification in the HIV-1 RNA genome whose function has been a matter of scientific debate is now confirmed to be key to the virus's ability to survive and thrive after infecting host cells, a new study has found.
Read more »
Common HIV treatments may aid Alzheimer's disease patientsAlzheimer's disease (AD) currently afflicts nearly seven million people in the U.S. With this number expected to grow to nearly 13 million by 2050, the lack of meaningful therapies represents a major unmet medical need.
Read more »
Project Determines HIV Epidemic Cannot Be Ended Without Stopping Former Prisoners and Other Patients Being Lost to CareThe global HIV epidemic cannot be ended without keeping former prisoners and other patients engaged in care, according to a project presented at ECCMID in Barcelona. Efforts made by HIV care clinics in Chicago to locate formerly incarcerated individuals living with HIV who dropped out of care and reconnect them with treatment services are outlined.
Read more »
COVID-19 found to increase the risk of severe cardiovascular problems in people with HIVA study led by the Centre for Epidemiological Studies on STIs and AIDS of Catalonia (CEEISCAT)—a group from the Germans Trias i Pujol Research Institute (IGTP), the Fundació Lluita contra les Infeccions (FLI), and Odense University Hospital (OUH)—has revealed that people living with HIV who have experienced an episode of COVID-19 face a...
Read more »
Study confirms how RNA chemical modifications benefit HIV-1A recent study has confirmed the positive effects of RNA chemical modifications on HIV-1. The research highlights the potential of these modifications in developing new treatments for the virus.
Read more »